Literature DB >> 14697986

Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma.

A A Onitilo1, J Lazarchick, C Y Brunson, D Frei-Lahr, R K Stuart.   

Abstract

As the life expectancy of patients with homozygous sickle cell anemia (SCA) improves, SCA care providers are confronted with diseases of the adult SCA population rarely seen before. We report here a 40-year-old woman with SCA who developed diffuse large B-cell non-Hodgkin's lymphoma (NHL) that was treated with eight cycles of chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE), without complete remission. She subsequently underwent high-dose cyclophosphamide and total-body irradiation followed by autologous bone marrow transplantation (BMT). To reduce the risk of sickle cell crisis precipitated by G-CSF, she underwent hypertransfusion to maintain a low % hemoglobin S throughout her treatment course. Although she has required iron chelation therapy and shows no sign of modification of her underlying SCA, she remains in remission from NHL 12 years posttransplant. To our knowledge, this is the first reported case of autologous BMT in a patient with SCA. Our patient illustrates that SCA in itself does not preclude autologous stem cell transplantation for lymphoma in selected patients, and this report should encourage others to consider autologous BMT in adults with SCA where it represents a lifesaving therapy for malignant diseases.

Entities:  

Mesh:

Year:  2003        PMID: 14697986     DOI: 10.1016/j.transproceed.2003.10.085

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

Authors:  Courtney D Fitzhugh; Matthew M Hsieh; Charles D Bolan; Carla Saenz; John F Tisdale
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

2.  Safety of pegfilgrastim (neulasta) in patients with sickle cell trait/anemia.

Authors:  Pashtoon Murtaza Kasi; Mrinal M Patnaik; Prema P Peethambaram
Journal:  Case Rep Hematol       Date:  2013-12-11

3.  Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion.

Authors:  Chantal Lagresle-Peyrou; François Lefrère; Elisa Magrin; Jean-Antoine Ribeil; Oriana Romano; Leslie Weber; Alessandra Magnani; Hanem Sadek; Clémence Plantier; Aurélie Gabrion; Brigitte Ternaux; Tristan Félix; Chloé Couzin; Aurélie Stanislas; Jean-Marc Tréluyer; Lionel Lamhaut; Laure Joseph; Marianne Delville; Annarita Miccio; Isabelle André-Schmutz; Marina Cavazzana
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.